 |
|
New evidence shows MabThera inhibits joint damage in patients with rheumatoid arthritis
June 22, 2006First RA drug to achieve these results in patients with an inadequate response to currently available treatments
New data presented at the EULAR meeting (European League Against Rheumatism) show for the first time that MabThera (rituximab), a unique B cell targeted therapy, is able to significantly inhibit structural damage of joints caused by rheumatoid arthritis (RA). The study was conducted in patients who had an inadequate response to one or more TNF inhibitors and they received either MabThera plus methotrexate (MTX) or MTX alone. X-ray evidence at 56 weeks showed that the progression of bone erosions and progression of narrowing of joint spaces in patients in the MabThera group were reduced by more than 50 % compared to patients receiving MTX alone (erosion scores of 0.59 and 1.32 respectively; joint space narrowing scores of 0.41 and 0.99 respectively).
Damage to the structure of the joints ultimately causes destruction of the joints and contributes to joint deformity and loss of mobility. Patients' ability to work and perform every day tasks such as getting dressed, walking and eating can be severely hampered.
Presenting the results, Professor Keystone, Rheumatology Department at the University of Toronto, Canada, said: "This is the first evidence demonstrating that MabThera can inhibit structural joint damage in patients with an inadequate response to one or more TNF inhibitors. Preventing structural damage is a critical outcome in treating rheumatoid arthritis. These X-ray data confirm MabThera as an effective and innovative therapy for patients with rheumatoid arthritis and highlight the value of targeting B cells."
Repeat treatment courses
Additional new data presented at EULAR demonstrate that repeat courses of MabThera in RA patients, 6 to 12 months after the initial course, provide continued improvement of symptoms across all clinical measures. Each treatment course consists of two infusions of 1000mg given two weeks apart. The challenging goal of treatment in RA is remission and, following a second course of MabThera in patients with an inadequate response to one or more TNF inhibitors, the number of patients achieving remission doubled from 6 % following an initial course to 13 % following a second course. A similar trend was seen for those achieving the hard-to-reach goal of a 70 % improvement in symptoms (ACR70), with responses increasing from 12 % following an initial course to 21 % following a second course.
Patient perspectives
Importantly, data presented at EULAR show improvements in clinical scores are reflected in patient reported outcomes.
"While it is important to a physician to address a disease from a clinical perspective, what matters most to the patient is whether they are able to function normally and how well they feel. For example, the impact of fatigue is often underestimated, but this is something which really impacts patients' lives. MabThera has demonstrated continuous improvements in physical and mental health aspects with repeated courses of therapy", said Professor Tak, Director, Division of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam, The Netherlands.
European League Against Rheumatism
Presenting the results, Professor Keystone, Rheumatology Department at the University of Toronto, Canada, said: "This is the first evidence demonstrating that MabThera can inhibit structural joint damage in patients with an inadequate response to one or more TNF inhibitors. Preventing structural damage is a critical outcome in treating rheumatoid arthritis. These X-ray data confirm MabThera as an effective and innovative therapy for patients with rheumatoid arthritis and highlight the value of targeting B cells."
Repeat treatment courses
Additional new data presented at EULAR demonstrate that repeat courses of MabThera in RA patients, 6 to 12 months after the initial course, provide continued improvement of symptoms across all clinical measures. Each treatment course consists of two infusions of 1000mg given two weeks apart. The challenging goal of treatment in RA is remission and, following a second course of MabThera in patients with an inadequate response to one or more TNF inhibitors, the number of patients achieving remission doubled from 6 % following an initial course to 13 % following a second course. A similar trend was seen for those achieving the hard-to-reach goal of a 70 % improvement in symptoms (ACR70), with responses increasing from 12 % following an initial course to 21 % following a second course.
Patient perspectives
Importantly, data presented at EULAR show improvements in clinical scores are reflected in patient reported outcomes.
"While it is important to a physician to address a disease from a clinical perspective, what matters most to the patient is whether they are able to function normally and how well they feel. For example, the impact of fatigue is often underestimated, but this is something which really impacts patients' lives. MabThera has demonstrated continuous improvements in physical and mental health aspects with repeated courses of therapy", said Professor Tak, Director, Division of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam, The Netherlands.
European League Against Rheumatism
Rheumatoid Arthritis Current Events and Rheumatoid Arthritis News RSSMultiple health concerns surface as winter, vitamin D deficiences arrive
A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic."
Researchers find new way to attack inflammation in Graves' eye disease
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab.
Pain thresholds linked to inflammation and sleep problems in arthritis patients
Despite recent advances in anti-inflammatory therapy, many rheumatoid arthritis (RA) patients continue to suffer from pain.
New therapy for vasculitis will help patients avoid infertility and cancer
Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy.
Strategy for mismatched stem cell transplants triggers protection against graft-vs.-host disease
A new technique being tested in stem-cell transplants from imperfectly matched donors has revealed a striking, unforeseen response that can suppress graft-versus-host disease, a common and dangerous complication of mismatched transplants, report scientists from Dana-Farber Cancer Institute.
Grains and lamb offer new sources of omega-3
CSIRO research on grains and lamb aimed at developing new dietary sources of long-chain omega-3 oils will be presented at the World Congress on Oils and Fats in Sydney this week.
Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award
A scientist at the La Jolla Institute for Allergy & Immunology has received one of the National Institutes of Health (NIH)'s top awards -- the 2009 NIH Director's Pioneer Award.
Experimental approach may reverse rheumatoid arthritis and osteoporosis
Researchers have identified a mechanism that may keep a well known signaling molecule from eroding bone and inflaming joints, according to an early study published online today in the Journal of Clinical Investigation.
Promising new target emerges for autoimmune diseases
University of Michigan scientists say they have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body's own cells.
New 'biofactories' produce rare healing substances in the endangered Devil's claw plant
Deep in Africa's Kalahari Desert lies the "Devil's claw," a plant that may hold the key to effective treatments for arthritis, tendonitis and other illnesses that affect millions each year.
More Rheumatoid Arthritis Current Events and Rheumatoid Arthritis News Articles
 |
The First Year: Rheumatoid Arthritis: An Essential Guide for the Newly Diagnosed (First Year, The) by M.E.A. McNeil (Author), Kenneth Sack MD (Foreword) Rheumatoid arthritis (RA), a disease characterized by inflammation of the joints, is one of the most disabling forms of arthritis and affects over two million people in the United States. Without proper treatment it can lead to long-term joint damage, chronic pain, loss of function, and disability. From the first moment of her diagnosis, author M.E.A. McNeil took charge and educated herself on every aspect of her condition. Now, as a "patient-expert," she guides those newly diagnosed step-by-step through their first year with RA. McNeil provides crucial information about the nature of the disease, treatment options, diet, exercise, social concerns, emotional issues, networking with others, and much more. The First Year—Rheumatoid Arthritis is an essential resource for everyone who wants... |
 |
The New Arthritis Breakthrough: The Only Medical Therapy Clinically Proven to Produce Long-term Improvement and Remission of RA, Lupus, Juvenile RS, Fibromyalgia, ... & Other Inflammatory Forms of Arthritis by Henry Scammell (Author) "...can be miraculous for rheumatoid arthritis sufferers."-- Health & Healing, Tomorrow's Medicine Today |
 |
Living with Rheumatoid Arthritis (Johns Hopkins Press Health Book) by Tammi L. Shlotzhauer MD (Author), James L. McGuire MD (Author), Carol M. Ziminski MD (Foreword) Already a trusted guide and an invaluable resource, Living with Rheumatoid Arthritis offers practical advice for the millions of people who live with this painful disease. Now thoroughly revised and expanded, this second edition brings readers up to date with the latest methods of diagnosis and treatment. Building on their accessible explanation of the disease and its causes, the authors describe the essential components of care: medication, joint protection, physical activity, and good nutrition. They provide a wealth of new information on medications, including biologic response–modifiers, alternative and complementary approaches, and treatments for osteoporosis (which often accompanies rheumatoid arthritis), and they describe safe and effective ways to cope with pain,... |
 |
Freedom from Rheumatoid Arthritis: The amazing story of one woman's recovery by Sonia St. Claire (Author) Freedom from Rheumatoid Arthritis is an inspirational book about survival. It tells the story of how one woman went from being a bed ridden cripple on and off for a year and a half, to reclaiming her health, happiness and quality of life stolen from her by this insidious disease. It is the story of a journey, a journey of discovery undertaken by one fiercely determined woman. A woman who has been to the depths and healed herself, and now with consummate compassion and grace, offers to share that process with you. This book includes a seven day menu, recovery and maintenance diet and recipes. |
 |
Synova Total Joint Care with Glucosamine, Chondroitin, MSM for Osteo and Rheumatoid Arthritis - 60 Coated Caplets by Next Nutraceuticals Synova Total Joint Care provides the latest clinically tested ingredients for the body's moveable joints, called synovial joints. The shoulder, elbow, wrist, fingers, hip, knee, ankle and toes are synovial joints. Synova Total Joint Care works to support joint health as well as joint flare-ups.* *Glucosamine HCl - a precursor for glycosaminoglycans, the primary component of joint cartilage. Glucosamine can help rebuild, renew and strengthen synovial joint cartilage.* *Joint Serum (Hyaluronic Acid) - HA is a natural component of synovial fluid found to increase joint viscosity, naturally helping to lubricate and re-hydrate joints.* *Methylsulfonylmethane (MSM) - a naturally occuring sulfur needed to form collagen, which is the protein found in all synovial connective... |
 |
Rheumatoid Arthritis: The Infection Connection {Targeting and Treating the Cause of Chronic Illness} by Katherine M. Poehlmann (Author) Foreword by Dr. Harold W. Clark, author of "Why Arthritis?" Appendices by Dr. Joseph Mercola (mercola.com) and Dr. Garth Nicolson (Institute for Molecular Medicine) Definitions of terms ****************************** EVERYTHING YOU NEED TO KNOW BEFORE CONSULTING YOUR DOCTOR! ****************************** A research scientist and former arthritis sufferer outlines a proven treatment that could banish your arthritis pain forever. This well-documented study presents evidence that rheumatoid arthritis (RA) and other chronic illnesses are caused by microbial infection. When the infection triggers allergic reactions, it appears that the body's immune system has turned on itself. Once the cause of the infection and allergies are identified and removed,... |
 |
The Arthritis Foundation's Guide to Good Living with Rheumatoid Arthritis, 3rd Edition by Dorothy Foltz-Gray (Author) From the Arthritis Foundation, a trusted source of health information and guidance for more than 50 years, Good Living With Rheumatoid Arthritis, 3rd Edition, explains new research and treatments in clear, simple language. Readers will learn how to be proactive patients, how to stretch daily to reduce pain and increase flexibility, and how to judge the many over-the-counter drugs and supplements on the market today. |
 |
Conquering Arthritis: What Doctors Don't Tell You Because They Don't Know: 9 Secrets I Learned the Hard Way by Barbara D. Allan (Author) This book provides hard-earned, practical, detailed information that is critical for successful healing of arthritis, but that has never before been collected in one book. Without this information many people with arthritis will not get well. The information is organized into a well-researched, easy-to-follow plan for getting well again and includes case histories of people with dramatic and lasting recoveries. It focuses not just on coping with the symptoms of arthritis, but on correcting its underlying causes using proven alternative medicine and pain management techniques. Anyone who is serious about healing from arthritis needs this book. |
 |
What To Do When The Doctor Says It's Rheumatoid Arthritis: Stop Your Pain, Become More Active, and Learn How to Talk to Your Doctors by Winnie Yu (Author), Harry D. Fischer (Author) Rheumatoid arthritis is a painful, incurable connective-tissue disease that attacks the hands, feet, and joints and may lead to deformities and permanent disabilities. This book, written by a doctor and health journalist will offer comprehensive medical advice and lifestyle information for the nearly three million Americans who suffer from this disease. The book uses mind-body techniques and alternative medicine to cope with the pain and discomfort, including information on: Pain relief Exercise Nutrition Managing your relationship with your doctors |
 |
Rheumatoid Arthritis by Marc C. Hochberg MD MPH (Author), Alan J. Silman MD (Author), Josef S. Smolen MD (Author), Michael E. Weinblatt MD (Author), Michael H. Weisman MD (Author) First Prize, Orthopaedics and Rheumatology, BMA Awards 2009 This state-of-the-art reference provides current insights into the etiology, diagnosis and management of rheumatoid arthritis. Leading international authorities in RA examine all of the latest scientific and clinical developments in understanding and managing this challenging disease, including new concepts in pathogenesis, epidemiology, risk factors, imaging, clinical outcomes and treatment. It's the guidance you need to offer optimal care to your patients with rheumatoid arthritis. Presents the work of leading international experts in rheumatoid arthritis for guidance you can trust. Provides the very latest understanding of the pathogenesis of rheumatoid arthritis, including molecular... |
| © 2009 BrightSurf.com |